Welcome to our dedicated page for Embecta SEC filings (Ticker: EMBC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Embecta Corp. filings document a Nasdaq-listed medical device and medical supplies company with common stock trading under EMBC. Its regulatory disclosures cover operating and financial results, capital-structure information, material-event reports, and governance matters tied to its board, annual meeting and executive-compensation votes.
Recent 8-K reports furnish quarterly and annual results and disclose director changes, board leadership roles and stockholder voting outcomes. Proxy materials describe annual meeting proposals, director elections, auditor ratification, compensation votes, and business context for Embecta's insulin injection franchise, restructuring actions, discontinued patch pump program, and broader medical supplies strategy.
Anderson Carrie L reported acquisition or exercise transactions in a Form 4 filing for EMBC. The filing lists transactions totaling 22,841 shares. Following the reported transactions, holdings were 64,581 shares.
HOMBACH ROBERT J. reported acquisition or exercise transactions in this Form 4 filing.
Embecta Corp. director Robert J. Hombach received an award of 22,841 shares of Embecta common stock on February 11, 2026 at a grant price of $0.00 per share. Following this grant, he directly beneficially owns 64,587.208 shares, which the filing notes include shares received as stock dividends.
Embecta Corp. director Morris Milton Mayo reported acquiring 22,841 shares of Embecta common stock on February 11, 2026. The shares were received as a grant or similar award at a price of $0.00 per share, meaning no cash was paid for the acquisition. Following this transaction, Mayo directly beneficially owns 60,121.34 Embecta common shares. The reported total includes shares that were received as stock dividends, so it reflects both prior holdings and dividend-related share accruals.
Embecta Corp. director Karen Prange reported an acquisition of 22,841 shares of common stock on February 11, 2026, as a grant or other award at a price of $0.00 per share. Following this transaction, she directly beneficially owned 64,581.208 shares. A footnote explains that the number of shares reported after the transaction includes shares she received as stock dividends.
Embecta Corp. director Claire Pomeroy reported an acquisition of 22,841 shares of common stock on February 11, 2026 as a grant, award, or other acquisition at a price of $0.00 per share. Following this transaction, she directly beneficially owns 66,127.164 shares. This total includes shares received as stock dividends.
Reidy Christopher R reported acquisition or exercise transactions in a Form 4 filing for EMBC. The filing lists transactions totaling 22,841 shares. Following the reported transactions, holdings were 70,122 shares.
Embecta Corp. reported the results of its 2026 Annual Meeting of Stockholders. All seven board nominees were elected to one-year terms, each receiving more than 45 million votes in favor, with several directors exceeding 48 million "For" votes.
Stockholders also ratified Ernst & Young LLP as the independent registered public accounting firm for fiscal 2026 with 53,083,728 votes in favor. On an advisory basis, stockholders approved executive compensation, and they approved an amendment to the 2022 Employee and Director Equity-Based Compensation Plan with 41,396,703 votes for and 7,034,781 against.
Embecta Corp. reported essentially flat revenue of $261.2M for the quarter ended December 31, 2025, down slightly from $261.9M a year earlier, but significantly higher profitability. Gross margin improved to 61.9%, lifting operating income to $83.3M from $28.7M.
Net income reached $44.1M versus break-even in the prior-year period, driven by lower research and development and restructuring costs and a $10.1M gain on the sale of patch pump intellectual property and assets. Operating cash flow was $17.2M, and cash and equivalents and restricted cash totaled $204.4M.
Embecta reduced its Term Loan by $37.5M in the quarter, leaving total principal debt of $1,379.3M and a weighted average borrowing cost of 6.1%. The company, a global diabetes injection-device provider, continues to face pricing pressure, shifting diabetes treatment patterns and macroeconomic uncertainty but reports compliance with all debt covenants.
Embecta Corp. reported essentially flat revenue of $261.2M for the quarter ended December 31, 2025, down slightly from $261.9M a year earlier, but significantly higher profitability. Gross margin improved to 61.9%, lifting operating income to $83.3M from $28.7M.
Net income reached $44.1M versus break-even in the prior-year period, driven by lower research and development and restructuring costs and a $10.1M gain on the sale of patch pump intellectual property and assets. Operating cash flow was $17.2M, and cash and equivalents and restricted cash totaled $204.4M.
Embecta reduced its Term Loan by $37.5M in the quarter, leaving total principal debt of $1,379.3M and a weighted average borrowing cost of 6.1%. The company, a global diabetes injection-device provider, continues to face pricing pressure, shifting diabetes treatment patterns and macroeconomic uncertainty but reports compliance with all debt covenants.
Embecta Corp. filed a current report to note that it released its financial results for the quarter ended December 31, 2025. The company issued a press release on February 5, 2026, and attached it as Exhibit 99.1, making the detailed quarterly results available to investors.
Embecta Corp. filed a current report to note that it released its financial results for the quarter ended December 31, 2025. The company issued a press release on February 5, 2026, and attached it as Exhibit 99.1, making the detailed quarterly results available to investors.
The Vanguard Group has filed an amended Schedule 13G reporting beneficial ownership of 4,617,610 shares of Embecta Corp common stock, representing 7.79% of the class as of 12/31/2025.
Vanguard reports no sole voting or dispositive power, with shared voting power over 567,466 shares and shared dispositive power over 4,617,610 shares. The shares are held on behalf of Vanguard’s clients, and no single other person has an interest in more than 5% of the class. Vanguard states the holdings are in the ordinary course of business and not for the purpose of changing or influencing control of Embecta.
The filing notes that on January 12, 2026, The Vanguard Group, Inc. underwent an internal realignment, after which certain subsidiaries or business divisions are expected to report beneficial ownership separately while pursuing the same investment strategies as before.